Next Article in Journal
Hereditary Neuropathy with Liability to Pressure Palsies: A Single-Center Experience in Southern Brazil
Previous Article in Journal
Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
 
 
Neurology International is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Neuropathic Pain Treatment: Still a Challenge

by
Osvaldo J.M. Nascimento
1,
Bruno L. Pessoa
1,*,
Marco Orsini
2,
Pedro Ribeiro
2,
Eduardo Davidovich
2,
Camila Pupe
1,
Pedro Moreira Filho
1,
Ricardo Menezes Dornas
1,
Lucas Masiero
1,
Juliana Bittencourt
2 and
Victor Hugo Bastos
3
1
Neuropathic Pain Division, Neurology/Neuroscience Clinical Research Subunit, Antonio Pedro University Hospital, Federal Fluminense University, Niterói, Brazil
2
Brain Mapping Department, Federal University of Rio de Janeiro, IPUB, Rio de Janeiro; Department of Medicine, SeverinoSombra University, Vassouras, Rio de Janeiro, Brazil
3
Piaui Federal University, Physical Therapy School, Brazil
*
Author to whom correspondence should be addressed.
Neurol. Int. 2016, 8(2), 6322; https://doi.org/10.4081/ni.2016.6322
Submission received: 24 November 2015 / Revised: 24 November 2015 / Accepted: 6 June 2016 / Published: 29 June 2016

Abstract

Neuropathic pain (NP) is the result of a series of conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of NP pathophysiology previously unexplored therapies have been used with encouraging results. In this group, acetyl-L-carnitine, alpha-lipoic-acid, cannabinoids, clonidine, EMA401, botulinum toxin type A and new voltage-gated sodium channel blockers, can be included. Besides, changing paradigms may occur with the advent of optogenetics and a better understanding of epigenetic regulation. We reviewed the published literature on the pharmacological treatment of NP. Despite the interesting results, randomized controlled trials are demanded the majority of the therapies previously mentioned. In spite of several studies for the relief of NP, pain control continues being a challenge.
Keywords: Neurology; pain; treatment Neurology; pain; treatment

Share and Cite

MDPI and ACS Style

Nascimento, O.J.M.; Pessoa, B.L.; Orsini, M.; Ribeiro, P.; Davidovich, E.; Pupe, C.; Filho, P.M.; Dornas, R.M.; Masiero, L.; Bittencourt, J.; et al. Neuropathic Pain Treatment: Still a Challenge. Neurol. Int. 2016, 8, 6322. https://doi.org/10.4081/ni.2016.6322

AMA Style

Nascimento OJM, Pessoa BL, Orsini M, Ribeiro P, Davidovich E, Pupe C, Filho PM, Dornas RM, Masiero L, Bittencourt J, et al. Neuropathic Pain Treatment: Still a Challenge. Neurology International. 2016; 8(2):6322. https://doi.org/10.4081/ni.2016.6322

Chicago/Turabian Style

Nascimento, Osvaldo J.M., Bruno L. Pessoa, Marco Orsini, Pedro Ribeiro, Eduardo Davidovich, Camila Pupe, Pedro Moreira Filho, Ricardo Menezes Dornas, Lucas Masiero, Juliana Bittencourt, and et al. 2016. "Neuropathic Pain Treatment: Still a Challenge" Neurology International 8, no. 2: 6322. https://doi.org/10.4081/ni.2016.6322

Article Metrics

Back to TopTop